Similar articles for PMID: 19282272

Year	Number of Results
1984	1
1986	1
1994	2
1995	1
1996	1
1998	3
1999	1
2000	1
2001	2
2004	3
2005	3
2006	8
2007	11
2008	4
2009	9
2010	13
2011	7
2012	4
2013	3
2014	5
2015	4
2016	7
2017	3
2018	3
2019	4
2020	1
2021	3
2022	6
2024	0

1

Mechanism of inhibition defines CETP activity: a mathematical model for CETP in vitro.

Potter LK, Sprecher DL, Walker MC, Tobin FL. Potter LK, et al. J Lipid Res. 2009 Nov;50(11):2222-34. doi: 10.1194/jlr.M900015-JLR200. Epub 2009 Mar 11. J Lipid Res. 2009. PMID: 19282272 Free PMC article.

2

Lipid transfer inhibitor protein defines the participation of lipoproteins in lipid transfer reactions: CETP has no preference for cholesteryl esters in HDL versus LDL.

Serdyuk AP, Morton RE. Serdyuk AP, et al. Arterioscler Thromb Vasc Biol. 1999 Mar;19(3):718-26. doi: 10.1161/01.atv.19.3.718. Arterioscler Thromb Vasc Biol. 1999. PMID: 10073979

3

The effect of cholesteryl ester transfer protein overexpression and inhibition on reverse cholesterol transport.

Tchoua U, D'Souza W, Mukhamedova N, Blum D, Niesor E, Mizrahi J, Maugeais C, Sviridov D. Tchoua U, et al. Cardiovasc Res. 2008 Mar 1;77(4):732-9. doi: 10.1093/cvr/cvm087. Epub 2007 Dec 4. Cardiovasc Res. 2008. PMID: 18056760

4

Cholesteryl ester transfer protein: An enigmatic pharmacology - Antagonists and agonists.

Yamashita S, Ruscica M, Macchi C, Corsini A, Matsuzawa Y, Sirtori CR. Yamashita S, et al. Atherosclerosis. 2018 Nov;278:286-298. doi: 10.1016/j.atherosclerosis.2018.09.035. Epub 2018 Oct 1. Atherosclerosis. 2018. PMID: 30347344 Review.

5

Inhibition of cholesteryl ester transfer protein increases cholesteryl ester content of large HDL independently of HDL-to-HDL homotypic transfer: in vitro vs in vivo comparison using anacetrapib and dalcetrapib.

Johns DG, Chen Y, Wang SP, Castro-Perez J, Previs SF, Roddy TP. Johns DG, et al. Eur J Pharmacol. 2015 Sep 5;762:256-62. doi: 10.1016/j.ejphar.2015.05.061. Epub 2015 Jun 3. Eur J Pharmacol. 2015. PMID: 26049012

6

Effects of cholesteryl ester transfer protein inhibitors on human lipoprotein metabolism: why have they failed in lowering coronary heart disease risk?

Schaefer EJ. Schaefer EJ. Curr Opin Lipidol. 2013 Jun;24(3):259-64. doi: 10.1097/MOL.0b013e3283612454. Curr Opin Lipidol. 2013. PMID: 23652567 Review.

7

Modulating cholesteryl ester transfer protein activity maintains efficient pre-β-HDL formation and increases reverse cholesterol transport.

Niesor EJ, Magg C, Ogawa N, Okamoto H, von der Mark E, Matile H, Schmid G, Clerc RG, Chaput E, Blum-Kaelin D, Huber W, Thoma R, Pflieger P, Kakutani M, Takahashi D, Dernick G, Maugeais C. Niesor EJ, et al. J Lipid Res. 2010 Dec;51(12):3443-54. doi: 10.1194/jlr.M008706. Epub 2010 Sep 22. J Lipid Res. 2010. PMID: 20861162 Free PMC article.

8

Selective CETP inhibition and PPARalpha agonism increase HDL cholesterol and reduce LDL cholesterol in human ApoB100/human CETP transgenic mice.

Hansen MK, McVey MJ, White RF, Legos JJ, Brusq JM, Grillot DA, Issandou M, Barone FC. Hansen MK, et al. J Cardiovasc Pharmacol Ther. 2010 Jun;15(2):196-202. doi: 10.1177/1074248410362891. Epub 2010 Mar 23. J Cardiovasc Pharmacol Ther. 2010. PMID: 20332533

9

Different effects of compounds decreasing cholesteryl ester transfer protein activity on lipoprotein metabolism.

Niesor EJ. Niesor EJ. Curr Opin Lipidol. 2011 Aug;22(4):288-95. doi: 10.1097/MOL.0b013e3283475e00. Curr Opin Lipidol. 2011. PMID: 21587074 Review.

10

JTT-705: is there still future for a CETP inhibitor after torcetrapib?

Rennings AJ, Stalenhoef A. Rennings AJ, et al. Expert Opin Investig Drugs. 2008 Oct;17(10):1589-97. doi: 10.1517/13543784.17.10.1589. Expert Opin Investig Drugs. 2008. PMID: 18808319 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

102 results

Results by year